Strongly self-interacting vector dark matter via freeze-in

We study a vector dark matter (VDM) model in which the dark sector couples to the Standard Model sector via a Higgs portal. If the portal coupling is small enough the VDM can be produced via the freeze-in mechanism. It turns out that the electroweak phase transition have a substantial impact on the prediction of the VDM relic density. We further assume that the dark Higgs boson which gives the VDM mass is so light that it can induce strong VDM self-interactions and solve the small-scale structure problems of the Universe. As illustrated by the latest LUX data, the extreme smallness of the Higgs portal coupling required by the freeze-in mechanism implies that the dark matter direct detection bounds are easily satisfied. However, the model is well constrained by the indirect detections of VDM from BBN, CMB, AMS-02, and diffuse $\gamma$/X-rays. Consequently, only when the dark Higgs boson mass is at most of ${\cal O}({\rm keV})$ does there exist a parameter region which leads to a right amount of VDM relic abundance and an appropriate VDM self-scattering while satisfying all other constraints simultaneously.Comment: 29 pages, 8 figure

Motsvarar första chefsrollen förväntningarna? -16 kvinnliga chefer berättar

Syfte: Syftet med undersökningen är att undersöka om unga högutbildade kvinnors uppfattningar och förväntningar inför första chefsrollen motsvarar den verklighet de möter; samt att kartlägga och diskutera eventuella skillnader och likheter. Metod: Denna studie är baserad på kvalitativ metod. Då vårt empiriska material har samlats in parallellt med sökandet efter teori kan vår ansats liknas vid en abduktiv. Slutsats: Förväntningarna inför första chefsrollen motsvaras sällan av verkligheten. I många fall har bilden av chefskapet varit felaktig. Främst påverkas denna bild av den närmsta omgivningen. Det finns få kvinnliga förebilder vilket medför en onyanserad bild av chefskapet. Den tunga administrativa bördan, avsaknaden av stöd från överordnade samt distansen till medarbetarna är exempel på sådant som förvånade cheferna. Några av cheferna upplever en ensamhet i sin nya roll. Kvinnorna har en inre drivkraft och chefsbefattningen attraherar dem då den ger dem en möjlighet att påverka. Prioriteringarna gällande kombinationen av familj och karriär är en stressfaktor och ett antal av cheferna upplever ett dömande ifrån samhället, i synnerhet ifrån andra kvinnor, på grund av deras prioriteringar. Partnern är ofta chef vilket innebär att det finns en förståelse för varandras arbetsbörda i relationen

Support for Social Change Among Members of Advantaged Groups: The Role of a Dual Identity Representation and Accepting Intergroup Contact

This preregistered research analyzed survey data from ethnic and religious advantaged groups in 12 countries ( N = 2,304) to examine the interplay between two determinants of support for social change toward intergroup equality. Drawing on the needs-based model and the common-ingroup identity model, we hypothesized that the experience of accepting intergroup contact and the endorsement of a dual identity representation of intergroup relations would be associated with greater support for equality. Furthermore, integrating the logic of both models, we tested the novel hypothesis that the positive effect of accepting contact on support for equality would be stronger under a high (vs. low) dual identity representation. While the predicted main effects received empirical support, we found no evidence for the expected interaction. These findings suggest that interventions to foster support for social change among advantaged group members can promote accepting contact and a dual identity representation independently of each other

Individual differences in system justification predict power and morality-related needs in advantaged and disadvantaged groups in response to group disparity

Guided by the needs-based model, we explored how individual differences in system justification predict group members’ needs in response to information about group-based disparities. Across two studies (N = 819), we found that among disadvantaged-group members (LGBTIQ* individuals/women) system justification was negatively related to need for power. Among advantaged-group members ([cis-]heterosexuals/men), system justification was negatively related to motivation to restore their ingroup’s moral essence (i.e., moral shame and wish that the ingroup would act more morally) but positively related to motivation to restore their ingroup’s moral image (i.e., need for positive moral image and expectation that the outgroup should acknowledge the ingroup’s morality). These results theoretically extend the needs-based model by offering a more nuanced picture of morality-related needs. Further, they underline the importance of considering individual differences in system justification for understanding advantaged- and disadvantaged-group members’ responses to social inequality

Response to Biologic Drugs in Patients with Rheumatoid Arthritis and Antidrug Antibodies

Importance: There are conflicting data on the association of antidrug antibodies with response to biologic disease-modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA). Objective: To analyze the association of antidrug antibodies with response to treatment for RA. Design, Setting, and Participants: This cohort study analyzed data from the ABI-RA (Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients) multicentric, open, prospective study of patients with RA from 27 recruiting centers in 4 European countries (France, Italy, the Netherlands, and the UK). Eligible patients were 18 years or older, had RA diagnosis, and were initiating a new bDMARD. Recruitment spanned from March 3, 2014, to June 21, 2016. The study was completed in June 2018, and data were analyzed in June 2022. Exposures: Patients were treated with a new bDMARD: adalimumab, infliximab (grouped as anti-tumor necrosis factor [TNF] monoclonal antibodies [mAbs]), etanercept, tocilizumab, and rituximab according to the choice of the treating physician. Main Outcomes and Measures: The primary outcome was the association of antidrug antibody positivity with EULAR (European Alliance of Associations for Rheumatology; formerly, European League Against Rheumatism) response to treatment at month 12 assessed through univariate logistic regression. The secondary end points were the EULAR response at month 6 and at visits from month 6 to months 15 to 18 using generalized estimating equation models. Detection of antidrug antibody serum levels was performed at months 1, 3, 6, 12, and 15 to 18 using electrochemiluminescence (Meso Scale Discovery) and drug concentration for anti-TNF mAbs, and etanercept in the serum was measured using enzyme-linked immunosorbent assay. Results: Of the 254 patients recruited, 230 (mean [SD] age, 54.3 [13.7] years; 177 females [77.0%]) were analyzed. At month 12, antidrug antibody positivity was 38.2% in patients who were treated with anti-TNF mAbs, 6.1% with etanercept, 50.0% with rituximab, and 20.0% with tocilizumab. There was an inverse association between antidrug antibody positivity (odds ratio [OR], 0.19; 95% CI, 0.09-0.38; P <.001) directed against all biologic drugs and EULAR response at month 12. Analyzing all the visits starting at month 6 using generalized estimating equation models confirmed the inverse association between antidrug antibody positivity and EULAR response (OR, 0.35; 95% CI, 0.18-0.65; P <.001). A similar association was found for tocilizumab alone (OR, 0.18; 95% CI, 0.04-0.83; P =.03). In the multivariable analysis, antidrug antibodies, body mass index, and rheumatoid factor were independently inversely associated with response to treatment. There was a significantly higher drug concentration of anti-TNF mAbs in patients with antidrug antibody-negative vs antidrug antibody-positive status (mean difference, -9.6 [95% CI, -12.4 to -6.9] mg/L; P < 001). Drug concentrations of etanercept (mean difference, 0.70 [95% CI, 0.2-1.2] mg/L; P =.005) and adalimumab (mean difference, 1.8 [95% CI, 0.4-3.2] mg/L; P =.01) were lower in nonresponders vs responders. Methotrexate comedication at baseline was inversely associated with antidrug antibodies (OR, 0.50; 95% CI, 0.25-1.00; P =.05). Conclusions and Relevance: Results of this prospective cohort study suggest an association between antidrug antibodies and nonresponse to bDMARDs in patients with RA. Monitoring antidrug antibodies could be considered in the treatment of these patients, particularly nonresponders to biologic RA drugs